Cure My Disease

Don't miss your cure!

 Log in / Sign up

Kidney hope: drug combo may slow alport disease

NCT ID NCT06499948

Completed Disease control Sponsor: Stefan Lujinschi Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed Phase 4 trial tested two drugs—dapagliflozin and spironolactone—alone and together in 12 adults with Alport syndrome, a genetic kidney disease. The goal was to see if these drugs could lower protein levels in urine, a key sign of kidney damage. Participants took each drug for 4 weeks, then both together, while continuing standard care. The study aims to find a way to delay kidney failure.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Dapagliflozin and Spironolactone
What this could lead to
If successful, this could point toward a new way to slow kidney disease progression in Alport syndrome by lowering protein in the urine.
What could go wrong
This is a very small, early-phase trial (12 people) with short treatment periods. Results may not apply to all patients, and the drugs may not show lasting benefit or could cause side effects like high potassium.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALPORT NEPHROPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Albuminuria Alport syndrome chronic renal failure syndrome hematuria, benign familial hematuria, benign familial, 1 hereditary nephritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALPORT NEPHROPATHY ALPORT SYNDROME THIN BASEMENT MEMBRANE DISEASE

Contacts and locations

Locations

  • Fundeni Clinical Institute

    Bucharest, Sector 2, 020021, Romania

More trials for these conditions

Other studies related to the condition(s) this trial covers.